Compounds > n,n,n-trimethylsphingosine
Page last updated: 2024-08-02 01:11:40

n,n,n-trimethylsphingosine

Description

Cross-References

ID SourceID
PubMed CID6439410
MeSH IDM0194392

Synonyms (5)

Synonym
n,n,n-trimethylsphingosine
4-octen-2-aminium, 1,3-dihydroxy-n,n,n-trimethyl-, (r-(r*,s*-(e)))-
138686-73-4
n,n,n-tms
[(e,2s,3r)-1,3-dihydroxyoct-4-en-2-yl]-trimethylazanium

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (81.25)18.2507
2000's3 (18.75)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (87.50%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
cilostazol
1
lactam;
tetrazoles		anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent		1991199133.0low001000
adenosine diphosphate
1
adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite		1994199430.0low001000
tetradecanoylphorbol acetate
4
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		1991199729.5medium004000
n-formylmethionine leucyl-phenylalanine
1
tripeptide1997199727.0low001000
arachidonic acid
1
icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid		Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite		1994199430.0low001000
sphingosine
16
sphing-4-eninehuman metabolite;
mouse metabolite		1991200827.1high0013300
n,n-dimethylsphingenine
7
aminodiol;
sphingoid;
tertiary amino compound		EC 2.7.1.91 (sphingosine kinase) inhibitor;
metabolite		1991200229.0high006100
sphingosine 1-phosphate
2
sphingoid 1-phosphatemouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent		1996199727.5low002000
mocetinostat
2
aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline		antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent		1996199827.0low002000
ristocetin
2
glycopeptide;
heterodetic cyclic peptide;
macrocycle;
tetrasaccharide derivative		antibacterial drug;
antimicrobial agent;
bacterial metabolite;
platelet-activating factor receptor agonist		1991199431.5low002000
sphingosine kinase
2
1996200225.0low001100
interleukin-8
1
1997199727.0low001000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
B16 Melanoma0
2
1991199431.5low002000
Benign Neoplasms0
1
1998199826.0low001000
Body Weight0
1
2007200717.0low000100
Cardiovascular Stroke0
2
1996200722.5low001100
Diabetes Mellitus, Adult-Onset0
1
2007200717.0low000100
Diabetes Mellitus, Type 20
1
2007200717.0low000100
Disease Models, Animal0
2
1998200721.5low001100
Extravascular Hemolysis0
1
1994199430.0low001000
Heart Disease, Ischemic0
1
1995199529.0low001000
Hemolysis0
1
1994199430.0low001000
Inflammation0
2
1997199826.5low002000
Injury, Ischemia-Reperfusion0
3
1996200723.7low002100
Injury, Myocardial Reperfusion0
4
1995200822.0low002200
Innate Inflammatory Response0
2
1997199826.5low002000
Leucocythaemia0
1
2002200222.0low000100
Leukemia0
1
2002200222.0low000100
Metastase0
3
1991199829.7low003000
Myocardial Infarction0
2
1996200722.5low001100
Myocardial Ischemia0
1
1995199529.0low001000
Necrosis0
1
1995199529.0low001000
Neoplasm Metastasis0
3
1991199829.7low003000
Neoplasms0
1
1998199826.0low001000
Obesity0
1
2007200717.0low000100
Reperfusion Injury0
3
1996200723.7low002100

Safety/Toxicity (1)

ArticleYear
Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
Cancer research, , Apr-15, Volume: 54, Issue:8		1994

Dosage (1)

ArticleYear
Liposomal N,N,N-trimethylsphingosine (TMS) as an inhibitor of B16 melanoma cell growth and metastasis with reduced toxicity and enhanced drug efficacy compared to free TMS: cell membrane signaling as a target in cancer therapy III.
Cancer research, , Apr-15, Volume: 54, Issue:8		1994